Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer

被引:327
作者
Budinska, Eva [1 ,2 ]
Popovici, Vlad [1 ,2 ]
Tejpar, Sabine [3 ]
D'Ario, Giovanni [1 ]
Lapique, Nicolas [1 ]
Sikora, Katarzyna Otylia [1 ]
Di Narzo, Antonio Fabio [1 ]
Yan, Pu [4 ]
Hodgson, John Graeme [5 ]
Weinrich, Scott [5 ]
Bosman, Fred [5 ]
Roth, Arnaud [6 ,7 ]
Delorenzi, Mauro [1 ,8 ]
机构
[1] SIB, Bioinformat Core Facil, CH-1015 Lausanne, Switzerland
[2] Masaryk Univ, Inst Biostat & Anal, CS-61137 Brno, Czech Republic
[3] Katholik Univ Leuven, Univ Hosp Gasthuisberg, Dept Oncol, Louvain, Belgium
[4] Univ Lausanne, Med Ctr, Univ Inst Pathol, CH-1015 Lausanne, Switzerland
[5] Pfizer Inc, Worldwide Res & Dev, Oncol Res Unit, La Jolla, CA USA
[6] Univ Hosp Geneva, Geneva, Switzerland
[7] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland
[8] Univ Lausanne, Med Ctr, Dept Format & Rech, CH-1015 Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
colorectal cancer; histopathology; gene expression; molecular heterogeneity; II COLON-CANCER; MICROSATELLITE INSTABILITY; POOR-PROGNOSIS; INDIAN HEDGEHOG; MESSENGER-RNA; BREAST-CANCER; STEM-CELLS; STAGE-II; DIFFERENTIATION; BIOINFORMATICS;
D O I
10.1002/path.4212
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The recognition that colorectal cancer (CRC) is a heterogeneous disease in terms of clinical behaviour and response to therapy translates into an urgent need for robust molecular disease subclassifiers that can explain this heterogeneity beyond current parameters (MSI, KRAS, BRAF). Attempts to fill this gap are emerging. The Cancer Genome Atlas (TGCA) reported two main CRC groups, based on the incidence and spectrum of mutated genes, and another paper reported an EMT expression signature defined subgroup. We performed a prior free analysis of CRC heterogeneity on 1113 CRC gene expression profiles and confronted our findings to established molecular determinants and clinical, histopathological and survival data. Unsupervised clustering based on gene modules allowed us to distinguish at least five different gene expression CRC subtypes, which we call surface crypt-like, lower crypt-like, CIMP-H-like, mesenchymal and mixed. A gene set enrichment analysis combined with literature search of gene module members identified distinct biological motifs in different subtypes. The subtypes, which were not derived based on outcome, nonetheless showed differences in prognosis. Known gene copy number variations and mutations in key cancer-associated genes differed between subtypes, but the subtypes provided molecular information beyond that contained in these variables. Morphological features significantly differed between subtypes. The objective existence of the subtypes and their clinical and molecular characteristics were validated in an independent set of 720 CRC expression profiles. Our subtypes provide a novel perspective on the heterogeneity of CRC. The proposed subtypes should be further explored retrospectively on existing clinical trial datasets and, when sufficiently robust, be prospectively assessed for clinical relevance in terms of prognosis and treatment response predictive capacity. Original microarray data were uploaded to the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress/) under Accession Nos E-MTAB-990 and E-MTAB-1026. (c) 2013 Swiss Institute of Bioinformatics. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
引用
收藏
页码:63 / 76
页数:14
相关论文
共 80 条
  • [1] [Anonymous], 2012, A language and environment for statistical computing
  • [2] Arnholt AlanT., 2012, BSDA: Basic Statistics and Data Analysis
  • [3] I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
    Barker, A. D.
    Sigman, C. C.
    Kelloff, G. J.
    Hylton, N. M.
    Berry, D. A.
    Esserman, L. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (01) : 97 - 100
  • [4] INTERRELATIONSHIP OF PROLACTIN AND ITS RECEPTOR IN CARCINOMA OF COLON AND RECTUM - A PRELIMINARY-REPORT
    BHATAVDEKAR, J
    PATEL, D
    GHOSH, N
    VORA, H
    SHAH, N
    KARELIA, N
    BALAR, D
    CHIKHLIKAR, P
    DAVE, R
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1994, 55 (04) : 246 - 249
  • [5] Expression Profiles in Stage II Colon Cancer According to APC Gene Status
    Birnbaum, David J.
    Laibe, Sophy
    Ferrari, Anthony
    Lagarde, Arnaud
    Fabre, Aurelie J.
    Monges, Genevieve
    Birnbaum, Daniel
    Olschwang, Sylviane
    [J]. TRANSLATIONAL ONCOLOGY, 2012, 5 (02): : 72 - 76
  • [6] Bolstad BM, 2004, INT REV NEUROBIOL, V60, P25
  • [7] Bosman FT., 2010, WHO CLASSIFICATION T
  • [8] Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters
    Chen, Yakun
    Tang, Yong
    Guo, Changxiong
    Wang, Jiuhui
    Boral, Debasish
    Nie, Daotai
    [J]. BIOCHEMICAL PHARMACOLOGY, 2012, 83 (08) : 1112 - 1126
  • [9] The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status
    Dahlin, Anna M.
    Palmqvist, Richard
    Henriksson, Maria L.
    Jacobsson, Maria
    Eklof, Vincy
    Rutegard, Jorgen
    Oberg, Ake
    Van Guelpen, Bethany R.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (06) : 1845 - 1855
  • [10] Single-cell dissection of transcriptional heterogeneity in human colon tumors
    Dalerba, Piero
    Kalisky, Tomer
    Sahoo, Debashis
    Rajendran, Pradeep S.
    Rothenberg, Michael E.
    Leyrat, Anne A.
    Sim, Sopheak
    Okamoto, Jennifer
    Johnston, Darius M.
    Qian, Dalong
    Zabala, Maider
    Bueno, Janet
    Neff, Norma F.
    Wang, Jianbin
    Shelton, Andrew A.
    Visser, Brendan
    Hisamori, Shigeo
    Shimono, Yohei
    van de Wetering, Marc
    Clevers, Hans
    Clarke, Michael F.
    Quake, Stephen R.
    [J]. NATURE BIOTECHNOLOGY, 2011, 29 (12) : 1120 - U11